CORONA Remedies FY26 PAT Up 33.4% to ₹199.4 Cr; Acquires WOKADINE
CORONA Remedies reported FY26 revenue of ₹1,403.2 Cr, up 17.3% YoY, and PAT of ₹199.4 Cr, up 33.4% YoY. Q4FY26 revenue grew 20.2% to ₹353.1 Cr, with PAT up 43.7% to ₹45.3 Cr. The company acquired WOKADINE, entering the ₹648 Cr Povidone Iodine market, and relaunched key brands.
The announcement details significant financial growth, a strategic acquisition, and portfolio expansion, which are material events likely to impact investor sentiment and the company's market position.
The company reported strong year-on-year growth in both revenue and profit for Q4FY26 and FY26. Strategic acquisitions and portfolio expansions were highlighted as key drivers of this positive performance.
CORONA Remedies Limited has announced its audited financial results for the fourth quarter and the full fiscal year ended March 31, 2026. The company reported strong financial performance, driven by focused brand-building initiatives, portfolio expansion, and operational efficiencies.
For Q4FY26, CORONA Remedies achieved a revenue growth of 20.2% year-on-year, reaching ₹353.1 crore, compared to ₹293.7 crore in Q4FY25. Profit After Tax (PAT) for the quarter surged by 43.7% to ₹45.3 crore from ₹31.5 crore in the same period last year. EBITDA for Q4FY26 stood at ₹62.0 crore, a 14.4% increase from ₹54.2 crore in Q4FY25.
For the full fiscal year FY26, revenue from operations grew by 17.3% to ₹1,403.2 crore, up from ₹1,196.4 crore in FY25. PAT for FY26 saw a significant increase of 33.4%, reaching ₹199.4 crore compared to ₹149.4 crore in the previous fiscal year. EBITDA for FY26 was ₹293.4 crore, a 22.3% rise from ₹240.0 crore in FY25.
Key strategic initiatives contributing to this performance include the acquisition of WOKADINE, marking CORONA's entry into the ₹648 crore Povidone Iodine market, funded through internal accruals. The company also relaunched key brands such as FosƟne R and Menodac in Women’s Health Therapeutics, and Noklot in the Cardiovascular segment, expanding its addressable market. Furthermore, CORONA established a dedicated team for the high-growth infertility segment and achieved a milestone with two brands crossing ₹100 crore in MAT revenue as of March 2026.
The company's industry ranking improved to 27th in India, a consistent upward movement of 5 spots over the last three years. The EAEU-GMP certification obtained by the company will enable entry into markets such as Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
Mr. Nirav K. Mehta, Managing Director & CEO of CORONA Remedies Limited, expressed optimism, stating, ‘FY26 has been a strong year for CORONA Remedies, marked by consistent revenue growth and enhanced operational efficiency. Our strategic focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning.’ He added that with initiatives like the WOKADINE acquisition and global accreditations, the company is well-positioned for sustainable growth.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.